Graffinity Enters into Drug Discovery Collaboration with Shionogi

摘要

Graffinity Pharmaceuticals GmbH, a member of the NovAliX group of companies, have announced that it has entered into a research collaboration with Osaka, Japan based Shionogi & Co, Ltd Under the terms of the agreement, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of various, novel small molecule hits against a key drug target.